Exact Sciences (NASDAQ:EXAS - Get Free Report) released its quarterly earnings results on Wednesday. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences updated its FY 2025 guidance to EPS.
Exact Sciences Price Performance
EXAS stock traded down $0.25 during midday trading on Friday, reaching $49.26. The company had a trading volume of 3,339,540 shares, compared to its average volume of 1,837,034. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a market capitalization of $9.15 billion, a P/E ratio of -8.84 and a beta of 1.24. The firm has a 50-day moving average price of $54.91 and a 200-day moving average price of $60.04.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on EXAS. Barclays decreased their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday. BTIG Research raised their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Craig Hallum reduced their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Piper Sandler reduced their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Finally, Sanford C. Bernstein raised their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $72.06.
Check Out Our Latest Stock Analysis on Exact Sciences
About Exact Sciences
(
Get Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
